Gilead (NASDAQ:GILD) just released data for a new hepatitis C combination therapy, and the results are staggering: a 100% cure rate! The news sent the stock soaring more than 13% on Monday. In this video, Motley Fool health care analyst Brenton Flynn breaks down the market potential for Gilead's new therapy and talks about another company with similarly excellent results that will want a share of that market for itself.
Gilead Hits the Jackpot With HCV Drug
By Brenton Flynn and Max Macaluso – Nov 13, 2012 at 7:59AM
NASDAQ: GILD
Gilead Sciences
Market Cap
$154B
Today's Change
(-2.11%) $2.62
Current Price
$121.46
Price as of October 22, 2025 at 3:58 PM ET